ClinicalTrials.gg
CompletedNCT03022045Updated Nov 18, 2021Results posted

A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

A Phase 3 interventional study of risankizumab in Psoriasis, sponsored by AbbVie. Completed at 9 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-11-18.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.

Enrollment
29th of 30
18 · median 162
Started
2017
with 2 others
Phase 3
17 of 30
none open now
Registered
10th of 30
by date
Lead sponsor
24 of 30
AbbVie

Among the 30 studies testing risankizumab in Psoriasis, this one is the 29th largest by enrollment, is one of 3 that started in 2017, is one of 17 in phase 3, and was the 10th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About risankizumab

risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing risankizumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the safety and efficacy of two different dose regimens of risankizumab for Japanese subjects with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).

Read the detailed description

Safety and efficacy data through 14 December 2017 are included in the interim analysis, which was conducted after all participants completed the Week 28 visit or discontinued from the study.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Generalized Pustular Psoriasis
  • Erythrodermic Psoriasis
  • risankizumab
  • Japanese
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For GPP

  • Have a diagnosis of GPP for at least 60 days prior to based on the diagnostic criteria of the Japanese Dermatological Association (JDA). Subjects not fulfilling one of the diagnostic criteria i.e., "accompanying systemic symptoms including fever or malaise" at the time of screening can be entered.
  • Subjects with an erythema area with pustules accounting for ≥ 10% of the body surface area (BSA), and with a severity assessment criteria score (JDA total score) specified by the JDA of less than 14.
  • Must be candidates for systemic therapy or phototherapy for GPP, as assessed by the investigator.

For EP

  • Have a diagnosis of EP prior to informed consent.
  • Subjects with an inflammatory erythema area accounting for ≥ 80% of the BSA at screening and at the time of the first administration of the study drug.
  • Must be candidates for systemic therapy or phototherapy for EP, as assessed by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Previous exposure to risankizumab.
  • Currently enrolled in another study or less than 30 days (from screening) since completing another investigational study (participation in observational studies is permitted).

For GPP

  • Subjects with active ongoing inflammatory diseases other than GPP that might confound trial evaluations according to investigator's judgment.

For EP

  • Subjects with active ongoing inflammatory diseases other than EP that might confound trial evaluations according to investigator's judgment.
  • Subject diagnosed with medication-induced or medication-exacerbated EP.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Risankizumab 75 mg

    Participants randomized to receive risankizumab 75 mg at Week 0, Week 4, and every 12 weeks up to Week 172.

    Drug: risankizumab

  • Experimental
    Risankizumab 150 mg

    Participants randomized to receive risankizumab 150 mg at Week 0, Week 4, and every 12 weeks up to Week 172.

    Drug: risankizumab

Interventions

  • risankizumab administered by subcutaneous injection

    Also known as: ABBV-066 BI 655066

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Generalized Pustular Psoriasis (GPP) Achieving GPP Clinical Response at Week 16

    GPP Clinical Response defined as at least "Slightly Improved" in the overall improvement rating from baseline according to Japanese Dermatological Association (JDA) total score for GPP. The JDA consists of an assessment of skin symptoms (area of skin with erythema, pustules, and edema) on a scale of 0 (none) to 9 (severe) and a systemic symptoms/assessment of test findings (fever, white blood count \[WBC\], serum C-reactive protein \[CRP\], and serum albumin) on a scale of 0 (none) to 8 (severe). The JDA total score is the sum of the 2 assessments ranging from 0 (mild) to 17 (severe). The overall improvement rating ranges from Markedly improved (decreased by ≥ 3 points) to Worsened (increased by ≥ 1 point); Slightly improved represents no change in points and ≥ 20% and \< 30% reduction of erythema area with pustules compared to baseline, or clinically meaningful improvement in ≥1 other parameters of the severity assessment criteria. Nonresponder imputation (NRI) was used for missing data.

    Time frame: Week 16

  2. Percentage of Participants With Erythrodermic Psoriasis (EP) Achieving EP Clinical Response at Week 16

    EP Clinical Response, defined as at least "Minimally Improved" in Clinical Global Impression-Global Improvement (CGI-GI) for EP. The CGI-GI is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-GI ratings are as follows: 0 (not assessed), 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), 7 (very much worse). NRI was used for missing data.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants With GPP Achieving GPP Clinical Response at Week 52

    GPP Clinical Response defined as at least "Slightly Improved" in the overall improvement rating from baseline according to JDA total score for GPP. The JDA consists of an assessment of skin symptoms (area of skin with erythema, pustules, and edema) on a scale of 0 (none) to 9 (severe) and a systemic symptoms/assessment of test findings (fever, WBC, serum CRP, and serum albumin) on a scale of 0 (none) to 8 (severe). The JDA total score is the sum of the 2 assessments ranging from 0 (mild) to 17 (severe). The overall improvement rating ranges from Markedly improved (decreased by ≥ 3 points) to Worsened (increased by ≥ 1 point); Slightly improved represents no change in points and ≥ 20% and \< 30% reduction of erythema area with pustules compared to baseline, or clinically meaningful improvement in ≥1 other parameters of the severity assessment criteria.

    Time frame: Week 52

  2. Percentage of Participants With EP Achieving EP Clinical Response at Week 52

    EP Clinical Response, defined as at least "Minimally Improved" in CGI-GI for EP. The CGI-GI is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-GI ratings are as follows: 0 (not assessed), 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), 7 (very much worse).

    Time frame: Week 52

  3. Percentage of Participants With GPP Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100.

    Time frame: Week 16

  4. Percentage of Participants With EP Achieving PASI90 at Week 16

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. NRI was used for missing data.

    Time frame: Week 16

  5. Percentage of Participants With GPP Achieving PASI90 at Week 52

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100.

    Time frame: Week 52

  6. Percentage of Participants With EP Achieving PASI90 at Week 52

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100.

    Time frame: Week 52

07

Results

Posted Feb 6, 2019

Participant flow

Participant flow — Overall Study
MilestoneRisankizumab 75 mgRisankizumab 150 mg
Started98
Completed86
Not completed12
Withdrew: Adverse event01
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryPercentage of Participants With Generalized Pustular Psoriasis (GPP) Achieving GPP Clinical Response at Week 16

GPP Clinical Response defined as at least "Slightly Improved" in the overall improvement rating from baseline according to Japanese Dermatological Association (JDA) total score for GPP. The JDA consists of an assessment of skin symptoms (area of skin with erythema, pustules, and edema) on a scale of 0 (none) to 9 (severe) and a systemic symptoms/assessment of test findings (fever, white blood count \[WBC\], serum C-reactive protein \[CRP\], and serum albumin) on a scale of 0 (none) to 8 (severe). The JDA total score is the sum of the 2 assessments ranging from 0 (mild) to 17 (severe). The overall improvement rating ranges from Markedly improved (decreased by ≥ 3 points) to Worsened (increased by ≥ 1 point); Slightly improved represents no change in points and ≥ 20% and \< 30% reduction of erythema area with pustules compared to baseline, or clinically meaningful improvement in ≥1 other parameters of the severity assessment criteria. Nonresponder imputation (NRI) was used for missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Generalized Pustular Psoriasis (GPP) Achieving GPP Clinical Response at Week 16
percentage of participantsGPP Risankizumab 75 mgGPP Risankizumab 150 mg
Percentage of Participants With Generalized Pustular Psoriasis (GPP) Achieving GPP Clinical Response at Week 16100100
PrimaryPercentage of Participants With Erythrodermic Psoriasis (EP) Achieving EP Clinical Response at Week 16

EP Clinical Response, defined as at least "Minimally Improved" in Clinical Global Impression-Global Improvement (CGI-GI) for EP. The CGI-GI is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-GI ratings are as follows: 0 (not assessed), 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), 7 (very much worse). NRI was used for missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Erythrodermic Psoriasis (EP) Achieving EP Clinical Response at Week 16
percentage of participantsEP Risankizumab 75 mgEP Risankizumab 150 mg
Percentage of Participants With Erythrodermic Psoriasis (EP) Achieving EP Clinical Response at Week 16100100
SecondaryPercentage of Participants With GPP Achieving GPP Clinical Response at Week 52

GPP Clinical Response defined as at least "Slightly Improved" in the overall improvement rating from baseline according to JDA total score for GPP. The JDA consists of an assessment of skin symptoms (area of skin with erythema, pustules, and edema) on a scale of 0 (none) to 9 (severe) and a systemic symptoms/assessment of test findings (fever, WBC, serum CRP, and serum albumin) on a scale of 0 (none) to 8 (severe). The JDA total score is the sum of the 2 assessments ranging from 0 (mild) to 17 (severe). The overall improvement rating ranges from Markedly improved (decreased by ≥ 3 points) to Worsened (increased by ≥ 1 point); Slightly improved represents no change in points and ≥ 20% and \< 30% reduction of erythema area with pustules compared to baseline, or clinically meaningful improvement in ≥1 other parameters of the severity assessment criteria.

Time frame:
Week 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants With EP Achieving EP Clinical Response at Week 52

EP Clinical Response, defined as at least "Minimally Improved" in CGI-GI for EP. The CGI-GI is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-GI ratings are as follows: 0 (not assessed), 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), 7 (very much worse).

Time frame:
Week 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants With GPP Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With GPP Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16
percentage of participantsGPP Risankizumab 75 mgGPP Risankizumab 150 mg
Percentage of Participants With GPP Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 1610075
SecondaryPercentage of Participants With EP Achieving PASI90 at Week 16

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. NRI was used for missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With EP Achieving PASI90 at Week 16
percentage of participantsEP Risankizumab 75 mgEP Risankizumab 150 mg
Percentage of Participants With EP Achieving PASI90 at Week 1660100
SecondaryPercentage of Participants With GPP Achieving PASI90 at Week 52

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100.

Time frame:
Week 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants With EP Achieving PASI90 at Week 52

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100.

Time frame:
Week 52

Results for this outcome have not been posted.

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 105 days after the last dose of study drug (up to 187 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GPP Risankizumab 75 mg0/4 (0%)0/4 (0%)4/4 (100%)
GPP Risankizumab 150 mg0/4 (0%)2/4 (50%)4/4 (100%)
EP Risankizumab 75 mg0/5 (0%)1/5 (20%)3/5 (60%)
EP Risankizumab 150 mg0/4 (0%)1/4 (25%)4/4 (100%)
Most frequent serious events
Most frequent serious events
EventGPP Risankizumab 75 mgGPP Risankizumab 150 mgEP Risankizumab 75 mgEP Risankizumab 150 mg
Alcoholic liver diseaseHepatobiliary disorders0/41/40/50/4
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/41/40/50/4
Calculus urinaryRenal and urinary disorders0/40/40/51/4
Adrenal insufficiencyEndocrine disorders0/40/41/50/4
Urinary tract infectionInfections and infestations0/40/41/50/4
Most frequent other events
Showing 10 of 35
Most frequent other events
EventGPP Risankizumab 75 mgGPP Risankizumab 150 mgEP Risankizumab 75 mgEP Risankizumab 150 mg
Viral upper respiratory tract infectionInfections and infestations1/41/43/53/4
Otitis mediaInfections and infestations0/40/40/52/4
DehydrationMetabolism and nutrition disorders0/42/40/50/4
Abdominal pain upperGastrointestinal disorders0/41/40/50/4
ConstipationGastrointestinal disorders0/41/41/50/4
VomitingGastrointestinal disorders0/41/40/50/4
InflammationGeneral disorders0/41/40/50/4
PyrexiaGeneral disorders0/41/40/50/4
Hepatic function abnormalHepatobiliary disorders1/41/40/50/4
Bronchitis viralInfections and infestations0/40/40/51/4

Baseline characteristics

Age, Continuous
Age, Continuous(years)Risankizumab 75 mgRisankizumab 150 mgTotal
Mean52.1 ± 20.7644.1 ± 20.1348.40 ± 20.24
Sex: Female, Male
Sex: Female, Male(Participants)Risankizumab 75 mgRisankizumab 150 mgTotal
Female123
Male8614
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Risankizumab 75 mgRisankizumab 150 mgTotal
Hispanic or Latino000
Not Hispanic or Latino9817
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Risankizumab 75 mgRisankizumab 150 mgTotal
American Indian or Alaska Native000
Asian9817
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

9 sites
  • Nagoya City University Hospital
    Nagoya-shi, Aichi 467-8602, Japan
  • Juntendo Univ Urayasu Hosp
    Urayasu Shi, Chiba 279-0021, Japan
  • Takagi Dermatological Clinic
    Obihiro, Hokkaido 080-0013, Japan
  • Mie University Hospital
    Tsu-shi, Mie 514-8507, Japan
  • Kansai Medical University Hospital
    Hirakata-shi, Osaka 573-1191, Japan
  • Shizuoka General Hospital
    静岡市, Shizuoka 〒420-8527, Japan
  • Tokyo Medical University Hosp
    Shinjuku-ku, Tokyo 160-0023, Japan
  • Fukuoka University Hospital
    Fukuoka, 814-0180, Japan
  • The University of Tokyo Hosp
    Tokyo, 113-0033, Japan
09

References and documents

Publications

  • Suleiman AA, Khatri A, Oberoi RK, Othman AA. Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis. Clin Pharmacokinet. 2020 May;59(5):575-589. doi: 10.1007/s40262-019-00829-2. PubMed 31667790 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Sep 2017, 7 months.

Results were first posted in Feb 2019, 1 year 4 months after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 7 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2017
First posted
Jan 16, 2017
StartActual
Jan 26, 2017
Primary completionActual
Sep 17, 2017
CompletionActual
Nov 19, 2020
Results first posted
Feb 6, 2019
Last update
Nov 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03022045
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jan 16, 2017
Start date
Jan 26, 2017
Primary completion
Sep 17, 2017
Completion
Nov 19, 2020
Results posted
Feb 6, 2019
Last update
Nov 18, 2021

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion